Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Has Consensus Target Price of $67.50

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) has been given an average rating of “Moderate Buy” by the six analysts that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $67.50.

ETON has been the subject of a number of analyst reports. Canaccord Genuity Group raised their target price on shares of Eton Pharmaceuticals from $60.00 to $68.00 and gave the company a “buy” rating in a research report on Friday, August 14th. HC Wainwright increased their price objective on shares of Eton Pharmaceuticals from $65.00 to $70.00 and gave the stock a “buy” rating in a research note on Friday, August 14th. B. Riley Financial restated a “buy” rating and set a $70.00 price objective (up from $40.00) on shares of Eton Pharmaceuticals in a research note on Friday, August 14th. Weiss Ratings upgraded Eton Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a report on Tuesday, September 22nd. Finally, Craig Hallum lifted their target price on Eton Pharmaceuticals from $40.00 to $62.00 and gave the company a “buy” rating in a research report on Tuesday, July 28th.

Insider Buying and Selling

In other news, Director Paul V. Maier sold 50,000 shares of the company’s stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $59.07, for a total transaction of $2,953,500.00. Following the sale, the director owned 59,745 shares in the company, valued at $3,529,137.15. This represents a 45.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider David Krempa sold 25,000 shares of the stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $65.07, for a total value of $1,626,750.00. Following the completion of the sale, the insider directly owned 37,025 shares of the company’s stock, valued at approximately $2,409,216.75. The trade was a 40.31% decrease in their position. The SEC filing for this sale provides additional information. 16.49% of the stock is owned by company insiders.

Hedge Funds Weigh In On Eton Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Squarepoint Ops LLC acquired a new stake in Eton Pharmaceuticals in the second quarter valued at $2,156,000. HighTower Advisors LLC grew its position in shares of Eton Pharmaceuticals by 187.2% in the 2nd quarter. HighTower Advisors LLC now owns 52,907 shares of the company’s stock valued at $1,915,000 after acquiring an additional 34,484 shares during the period. Sigma Planning Corp acquired a new position in shares of Eton Pharmaceuticals during the 2nd quarter worth about $1,086,000. Toth Financial Advisory Corp acquired a new position in shares of Eton Pharmaceuticals during the 2nd quarter worth about $43,000. Finally, Navellier & Associates Inc. bought a new stake in shares of Eton Pharmaceuticals in the 2nd quarter valued at about $652,000. 27.86% of the stock is currently owned by institutional investors and hedge funds.

Eton Pharmaceuticals Trading Up 0.0%

NASDAQ:ETON opened at $59.19 on Friday. Eton Pharmaceuticals has a twelve month low of $14.27 and a twelve month high of $66.37. The company has a quick ratio of 1.30, a current ratio of 1.52 and a debt-to-equity ratio of 0.41. The business has a 50 day moving average price of $54.36 and a two-hundred day moving average price of $38.34. The company has a market cap of $1.69 billion, a P/E ratio of 155.76 and a beta of 0.90.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its quarterly earnings data on Thursday, August 13th. The company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.19 by $0.24. The company had revenue of $37.59 million for the quarter, compared to the consensus estimate of $27.11 million. Eton Pharmaceuticals had a net margin of 12.02% and a return on equity of 40.13%. As a group, analysts expect that Eton Pharmaceuticals will post 1.13 EPS for the current fiscal year.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for underserved patient populations, with an emphasis on pediatric, rare disease and other difficult-to-treat conditions. The company generally pursues products with established clinical or regulatory pathways and works to bring them to market through its own commercial operations or strategic partnerships.

Eton’s marketed portfolio includes Eprontia, an oral solution formulation of topiramate used in the treatment of certain seizure disorders; Biorphen, an injectable phenylephrine product used to treat clinically important low blood pressure; and Alkindi Sprinkle, a hydrocortisone granule product for replacement therapy in children with adrenal insufficiency.